Medicinal Products

740. Deputy Natasha Newsome Drennan asked the Minister for Health if a proposal for the reimbursement of vamorolone (Agamree) under the HSE drug reimbursement scheme has been submitted to the HSE Drugs Group; and if she will make a statement on the matter. [47252/26]

741. Deputy Séamus McGrath asked the Minister for Health for an update on the approval of a drug for Von Hippel Lindau syndrome [47257/26]

802. Deputy Niamh Smyth asked the Minister for Health if she will provide an update on the reimbursement process for skyclarys for the treatment of Friedreich's Ataxia; the meetings that have taken place to date regarding the application; when a final decision is expected; and if she will make a statement on the matter. [47506/26]

805. Deputy John Brady asked the Minister for Health if she will intervene to ensure that the HSE prioritises a conclusion to the skyclarys reimbursement negotiations; if she will commit to the inclusion of the drug on the agenda of the next HSE drugs group meeting; and if she will make a statement on the matter. [47509/26]

898. Deputy Colm Burke asked the Minister for Health the steps being taken to ensure that a life-changing prostate cancer medication, RLT, known as Pluvicto, will be made available to medically suitable patients; and if she will make a statement on the matter. [47846/26]

899. Deputy Joe Neville asked the Minister for Health to update Dáil Éireann on the 10 June 2026 statement of the Beneluxa countries on a unified approach to access to and affordability of medicines; her Department’s engagement in 2026 with Beneluxa countries on this initiative; the possible advancements in pharmaceutical procurement across the Beneluxa countries in 2026 and 2027; and if she will …

457. Deputy Aengus Ó Snodaigh asked the Minister for Health when selpercatinib (details supplied) will be made available here. [46451/26]

471. Deputy Paul Lawless asked the Minister for Health the reason a commonly prescribed diuretic water tablet has been removed from the list of medications covered under the medical card and/or drugs payment scheme (details supplied); the number of patients affected by this change; whether an impact assessment was carried out in advance of this decision, particularly in relation to patients with c…

472. Deputy Pádraig Mac Lochlainn asked the Minister for Health the current status of the reimbursement process for givinostat for children living with Duchenne muscular dystrophy; the steps being taken to ensure urgent access, clear timelines and no further delays; and if she will make a statement on the matter. [46503/26]

485. Deputy Pádraig O'Sullivan asked the Minister for Health whether the medicine belzutifan (welireg) is available for the treatment of patients with Von Hippel-Lindau disease in Ireland; whether it is eligible for reimbursement by the HSE; and if she will make a statement on the matter. [46535/26]

486. Deputy Pádraig O'Sullivan asked the Minister for Health whether the medicine daraxonrasib is available for the treatment of patients with pancreatic cancer in Ireland; whether it is or will be eligible for reimbursement by the HSE; and if she will make a statement on the matter. [46536/26]

185. Deputy Holly Cairns asked the Minister for Health the status of public funding application for a medication (details supplied) when prescribed in the treatment of the chronic inflammatory condition eosinophilic esophagitis (EoE); and if she will make a statement on the matter. [45990/26]

188. Deputy Louis O'Hara asked the Minister for Health whether the reimbursement of the drug skyclarys was included in the agenda for the June meeting of the HSE's Drugs Groups; if not, the rationale for its exclusion; to provide an update on the process of adjudicating whether the cost of skyclarys will be reimbursed; and if she will make a statement on the matter. [46002/26]

211. Deputy Pádraig Rice asked the Minister for Health if the consideration of skyclarys for the treatment of Friedreich's ataxia will be prioritised; the date on which the drug will be on the agenda for a meeting of the HSE Drugs Group; and if she will make a statement on the matter. [46123/26]

212. Deputy Peter 'Chap' Cleere asked the Minister for Health further to Parliamentary Question No. 859 of 6 May 2026, if the HSE will issue a response to this Deputy as soon as possible. [46142/26]

821. Deputy Conor Sheehan asked the Minister for Health the reason Skyclarys is not included on the agenda for the upcoming HSE drugs group meeting; if this drug will be put on the agenda for this meeting; and if she will make a statement on the matter. [44885/26]

823. Deputy Paul Nicholas Gogarty asked the Minister for Health the actions she is taking in liaison with the HSE to ensure a timely pricing and reimbursement scheme for givinostat (duvyzat), given that it is a year since conditional marketing authorisation was granted and it is a year since she met with families of children with DM and MDI and six months since she spoke at a national conference (…

824. Deputy Paul Nicholas Gogarty asked the Minister for Health the reasons provided by the HSE regarding the delay in processing the pricing and reimbursement application for givinostat, especially since 15 January 2026 when a full HTA dossier was submitted by a company (details supplied) to the NCPE; and if she will make a statement on the matter. [44892/26]

825. Deputy Paul Nicholas Gogarty asked the Minister for Health if she has been briefed by the HSE Drugs Group which was due to meet on 10 June 2026 to consider givinostat for reimbursement; if clear timelines for rollout have now been provided; if there will be proactive engagement with the HSE and clinical teams to ensure planning begins urgently, in order that implementation does not become a f…

826. Deputy Paul Nicholas Gogarty asked the Minister for Health the steps she has taken to ensure that eligibility criteria for givinostat are aligned with the NICE approach, ensuring access for boys who can walk or who can stand with or without support, in order that boys here are not disadvantaged compared to those in the Northern Ireland and receive equitable access to treatment; and if she wil…

830. Deputy Eoghan Kenny asked the Minister for Health if her Department has further considered the inclusion of Skyclarys (omaveloxolone) as of June 2026, which is a treatment for Friedreich's ataxia in a reimbursement scheme given the cost of the drug and the fact that other European countries provide this scheme to patients; and if she will make a statement on the matter. [44904/26]

832. Deputy Claire Kerrane asked the Minister for Health to provide an update on access to givinostat; and if she will make a statement on the matter. [44908/26]

833. Deputy Claire Kerrane asked the Minister for Health if she will consider including mounjaro on the medical card scheme for medical card holders aged over 70; and if she will make a statement on the matter. [44909/26]

836. Deputy Michael Fitzmaurice asked the Minister for Health the status of gaining access to givinostat for boys living with Duchenne muscular dystrophy; and if she will make a statement on the matter. [44919/26]

838. Deputy Claire Kerrane asked the Minister for Health the steps she will take to ensure that the HSE recognises and responds to the time-critical nature of Friedreich's ataxia during the current price negotiations for Skyclarys; and if she will make a statement on the matter. [44928/26]